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Abstract 
 
The rapid spread of azithromycin resistance in sexually transmitted infections caused 
by Mycoplasma genitalium is a growing concern. It is not yet clear to what degree 
macrolide resistance in M. genitalium results from the emergence of de novo 
mutations or the transmission of resistant strains. We analysed epidemiological data 
and developed a compartmental model to investigate the contribution of de novo 
macrolide resistance mutations to the spread of antimicrobial resistant M. 
genitalium. We fitted the model to data from France, Sweden and Denmark and 
estimated treatment rates and the time point of azithromycin introduction. In a 
meta-analysis of six studies, we estimated that de novo resistance develops in 12% 
(95% CI 7–17%, I2 44%) of azithromycin treated M. genitalium infections. Our model 
shows that the high probability of de novo resistance accelerates the spread of 
antimicrobial resistant M. genitalium in comparison with lower probabilities. The 
estimated per capita treatment rate in France   was lower than in Denmark and 
Sweden but confidence intervals for the three estimates overlap. The estimated 
dates of introduction of azithromycin in each country are consistent with published 
reports. We conclude that clinical management strategies for M. genitalium should 
seek to limit the unnecessary use of macrolides. 
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Introduction 
Antimicrobial resistant Mycoplasma genitalium infections are increasingly common 
in many countries [1–14]. M. genitalium is a sexually transmitted bacterium which, 
together with Chlamydia trachomatis, is an important cause of non-gonococcal 
urethritis (NGU) in men and of cervicitis in women [15, 16]. M. genitalium is 
detected using nucleic acid amplification tests (NAATs), which were first developed 
during the 1990s as research tools because the bacterium is slow-growing and 
extremely hard to culture. In most clinical settings, NAATs for M. genitalium 
diagnosis are not available. The clinical syndrome of NGU is treated empirically, with 
a single 1g dose of azithromycin recommended for first line treatment in many 
countries since the late 1990s [17].  
Macrolide resistance in M. genitalium results from a single nucleotide mutation in 
region V of the 23S rRNA gene, most commonly A2058G or A2059G. Jensen et al. 
identified these mutations in Australian and Swedish men, with NGU caused by M. 
genitalium, who did not respond to azithromycin [18]. In seven of nine patients who 
experienced clinical treatment failure with a single 1g dose of azithromycin, and who 
carried a wild-type organism before treatment, post-treatment specimens contained 
mutations in the 23S rRNA gene that conferred macrolide resistance [18]. Since then, 
other investigators have also detected macrolide resistance mutations de novo (also 
known as acquired, induced or selected) in M. genitalium [8, 11, 23–25].  
In many European countries, the proportion of resistant infections approaches 50% 
[9, 10, 12]. A study in Greenland that reported on specimens collected from 2008 to 
.CC-BY 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/321216doi: bioRxiv preprint first posted online May. 24, 2018; 
 4 
2009 found that all specimens with M. genitalium harboured macrolide resistance 
mutations [9]. In Sweden, where azithromycin has only recently been recommended 
to treat laboratory diagnosed M. genitalium infections, the proportion of 
azithromycin resistant M. genitalium increased in one study from zero in 2006 to 
21% in 2011 [10]. The increase in azithromycin resistance can explain a fall in 
microbiological cure of M. genitalium, from around 85% in studies published from 
2000 to 2009 to around 67% from 2010 to 2015 [22, 23]. It is not yet clear to what 
degree the level of treatment failure in M. genitalium results from the emergence of 
de novo resistance mutations or the transmission of resistant strains. The objective 
of this study was to investigate the role of de novo emergence of resistance in the 
spread of azithromycin resistant M. genitalium.  
Methods 
We analysed epidemiological data about the proportion of M. genitalium infections 
with de novo mutations conferring macrolide resistance and about trends in the 
prevalence of M. genitalium resistance. We used the findings to inform the 
development of a mathematical model of the transmission of M. genitalium, which 
we fitted to resistance data. We used R 3.3.2 [24] for statistical analyses, 
transmission model simulations and parameter inference. We define de novo as a 
change from a drug-susceptible infection before treatment to a drug-resistant 
infection after treatment, either by selection of one or a few pre-existing resistant 
mutants in an otherwise drug-susceptible bacterial population or due to a novel 
resistance mutation evolving during drug exposure. 
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Epidemiological data  
We searched Pubmed in March 2018 and updated the search on 4th May 2018. We 
used the medical subject headings Mycoplasma genitalium AND drug resistance, 
bacterial and found 67 publications. Two authors independently screened the 
records for original research articles that provided data to address two questions. 
1. Probability of emergence of de novo resistance: we included all studies that 
investigated patients with M. genitalium who received a single 1g dose of 
azithromycin and who had both pre- and post-treatment specimens tested for 
macrolide resistance mutations. From each included study we extracted the 
number of patients with macrolide resistance mutations detected only after 
treatment and the total number of patients tested. We combined the results 
from included studies in a meta-analysis. We used the Freeman-Tukey double 
arcsine transformation and used a random effects model to estimate the average 
proportion (with 95% confidence intervals, CI) of patients with initially macrolide 
susceptible M. genitalium who had macrolide resistance mutations detected 
after treatment (metaprop function from the R package meta 4.9).  
2. Time trend in proportion of azithromycin resistant M. genitalium infections: we 
identified countries for which data about the proportion of specimens with 
macrolide resistance mutations from the same region or from an entire country 
were reported for more than three years. We selected three countries that used 
different strategies to test and treat M. genitalium. For each country, we 
recorded the region, M. genitalium testing strategy and treatment regimen, year 
in which azithromycin was introduced for the treatment of M. genitalium and, 
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for each year, the total number of specimens with positive test results for M. 
genitalium and the number with macrolide resistance mutations. We contacted 
the study authors if this information was not available in the publication. For 
each year, we calculated the proportion (with 95% CI) of azithromycin resistant 
M. genitalium. 
Mathematical model  
We developed a mathematical model that simulates the spread of drug resistance 
within a population (Figure 1). The model consists of three compartments: 
susceptibles (S), people infected with a drug-susceptible strain of M. genitalium (IS), 
and people infected with a drug-resistant strain of M. genitalium (IR).  
 
 
 
 
 
 
 
 
Assuming a homogenous population without demography, the transmission 
dynamics can be described by the following ordinary differential equations: 
 
𝑑𝑆
𝑑𝑡
=  −𝛽𝑆(𝐼𝑆 + 𝐼𝑅) + 𝛾(𝐼𝑆 + 𝐼𝑅) + (1 − 𝜇)𝜒𝐼𝑆 (1) 
Figure 1. Structure of the epidemiological model for M. genitalium. 
S IS 
β × IS 
γ 
χ × (1 – μ) 
IR 
β × IR 
γ 
χ × μ 
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𝑑𝐼𝑆
𝑑𝑡
= 𝛽𝑆𝐼𝑆 − (𝛾 + 𝜒)𝐼𝑆 (2) 
𝑑𝐼𝑅
𝑑𝑡
= 𝛽𝑆𝐼𝑅 − 𝛾𝐼𝑅 + 𝜒𝜇𝐼𝑆 (3) 
where β is the transmission rate, which is assumed to be independent of the type of 
M. genitalium strain. Both types of infections can clear naturally at a rate γ. Patients 
receive treatment at a rate χ. The treatment rate is defined as all occasions of 
treatment with a single 1g dose of azithromycin in a person infected with M. 
genitalium, either with or without symptoms. µ denotes the probability of de novo 
resistance emergence during treatment. The de novo emergence of resistance also 
implies that the treatment failed. We used the point estimate of the probability of de 
novo resistance emergence from the meta-analysis. For simplicity, we assumed that 
there is no second-line treatment for resistant infections, which can thus only clear 
naturally. 
The rate at which the drug-resistant strain replaces the drug-susceptible in a 
population can be expressed by the difference in the net growth rates (∆𝜑) between 
the two strains [27, 28]: 
∆𝜑 = 𝜑𝑅 − 𝜑𝑆 (4) 
∆𝜑 = (𝛽𝑆 − 𝛾 +
𝜒𝜇𝐼𝑆
𝐼𝑅
) − (𝛽𝑆 − 𝛾 − 𝜒) (5) 
∆𝜑 =  𝜒 (1 +
𝜇𝐼𝑆
𝐼𝑅
) (6) 
Model parameters 
The natural clearance rate (γ) of M. genitalium infections has not been established 
and findings from empirical studies are inconsistent [27]. Based on values for other 
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bacterial sexually transmitted infections, the natural clearance rate is likely to be at 
least in the order of months or years. We set the natural clearance rate γ to 0.8 y-1, a 
published estimate based on epidemiological data and mathematical modelling [27], 
and the infection rate ,β, to 0.816 person-1 y-1. These values result in an equilibrium 
prevalence of M. genitalium infections of about 2% in the absence of any treatment, 
which is consistent with estimates of the prevalence of M. genitalium in the sexually 
active population in high-income countries [28, 29]. The values for the natural 
clearance rate and the prevalence of infection do not govern the relative growth rate 
of the drug-resistant proportion (Equation 6), so they do not influence the relative 
prevalence of resistant infections or estimates of the treatment rate in our model. 
We did not find any published evidence of the effect of macrolide resistance on the 
fitness of M. genitalium strains, so we assumed that any fitness reduction is 
negligible and that resistant infections have the same infectivity as wild-type 
infections. 
Table 1. Model parameters  
Parameter Description Value Source 
β Transmission rate 0.816 person-1 y-1 See text 
γ Natural clearance rate 0.8 y-1 [27] 
χ Treatment rate Estimated  
μ Probability of de novo 
resistance during treatment 
12% 
(95% CI: 7–17%) 
Meta-analysis of 
[3, 6, 19–21, 29], 
see Results 
Model fitting and simulations 
We fitted the transmission model to country-specific resistance data to obtain 
maximum likelihood estimates of the treatment rate χ and the time point T for the 
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introduction of azithromycin. Given a model-predicted proportion of resistant strains 
𝑝𝑖 =
𝐼𝑅(𝑖)
𝐼𝑆(𝑖)+𝐼𝑆(𝑖)
 in year i, the log-likelihood to find ki resistant samples in Ni tested 
individuals is: 
𝐿(𝜒, 𝑇) = ∑ (log (
𝑁𝑖
𝑘𝑖
) + 𝑘𝑖 log 𝑝𝑖 + (𝑁𝑖 − 𝑘𝑖)log (1 − 𝑝𝑖)) . (7) 
Simulations start at time T with 98% uninfected people, 2% people with drug 
susceptible infections and no people with initial drug-resistant infections, which is 
the steady state prevalence in our model with our assumed clearance rate and 
infection rate in the absence of treatment. We used log-transformed parameters for 
the estimation and stipulated that the upper limit of T could not be beyond the time 
point where resistance was first observed. We derived simulation-based 95% 
confidence intervals for the model curve from 10,000 bootstrap samples from the 
multivariate normal distribution of the two parameters. 
We also investigated the contribution of the probability of de novo resistance 
emergence to the rise in the proportion of resistant infections by simulating 
scenarios with probabilities that differed from that estimated in the meta-analysis. 
First, we kept the model-derived maximum likelihood estimates of χ and T but set 
the probability of de novo resistance emergence, μ = 1% or μ = 0.1%. Second, we set 
the probability of de novo resistance emergence, μ = 1% or μ = 0.1% and fitted the 
model to the time trend data and obtained a new estimate of the treatment rate.  
We used the ode function from the R package deSolve 1.20 to solve the ordinary 
differential equations, and the mle2 function from the R package bbmle 1.0.19 using 
the Nelder-Mead method for log-likelihood optimisation. 
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Results 
Data 
Probability of emergence of de novo resistance in M. genitalium 
We included six studies that estimated the probability of de novo resistance 
emergence [7, 10, 19–21, 30] (supplementary table 1)Error! Reference source not 
found.. In five out of six studies, amongst patients with wild-type infection before 
treatment, macrolide resistance mutations were found in all patients with persistent 
detection of M. genitalium after treatment. Ito et al. reported three patients who 
failed treatment while no resistance mutations were detected [30]. In the studies by 
Anagrius et al. [10] and Falk et al. [20], we excluded three patients each for whom 
the pre- or post-treatment samples were missing or inconclusive. The summary 
estimate of the average probability of de novo resistance (µ) was 12% (95% CI: 7 – 
17%) per treatment, with mild between study heterogeneity. 
 
Figure 2. Probability of de novo emergence of azithromycin resistance in M. 
genitalium, estimated by random effects meta-analysis of treatment studies 
reporting pre-treatment susceptibility to azithromycin [7, 10, 19–21, 30]. 
 
Time trend in proportion of azithromycin resistant M. genitalium infections  
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We included five studies that provided data about the proportion of azithromycin-
resistant M. genitalium infections over time and the management of M. genitalium 
infection in France [3, 8, 31], Denmark [13] and Sweden [10] (supplementary table 
2). Study authors provided additional information about Denmark, for which data 
were pooled across consecutive years and Sweden, for which the numbers of 
patients per year as well as data for 2012 and 2013 were provided [10, 13].  
In France, we included three studies with data from 314 patients (310 from 
Bordeaux) from 2003 to 2012 [3, 8, 31]. None of 17 M. genitalium positive 
specimens from 2003 to 2005 contained macrolide resistance mutations. From 2006 
onwards, mutations were detected in 10% to 17% of specimens tested in each year. 
In France, azithromycin was introduced for first line treatment of NGU in the 1990s 
[32]. For Denmark, one study reported nationwide data from 1,008 patients with M. 
genitalium detected from 2006 to 2010, with 27% to 42% of specimens containing 
macrolide resistance mutations [13]. In Denmark, 1g single dose azithromycin is 
routinely prescribed for treatment of NGU; erythromycin was the first line treatment 
before azithromycin became available. An extended azithromycin regimen is 
prescribed if a M. genitalium infection was diagnosed and NAAT for detection of M. 
genitalium infections have been available since 2003 [13]. In Sweden, we analysed 
one study with data about macrolide resistance mutations from 408 samples 
obtained from 2006 to 2013 from patients at a single clinic in Falun [10]. Macrolide 
resistance mutations were first detected in a single specimen in 2008 and increased 
to 16% of 95 specimens in 2011. In Sweden, doxycycline is used as first line 
treatment for NGU [18, 32]. Azithromycin is used only when M. genitalium is 
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identified as the cause, with testing introduced in the 2000s [10].  
Model  
The transmission model fitted the increase in M. genitalium resistance in France, 
Denmark and Sweden well (Figure 3). Our analysis shows that the rise in the 
proportion of azithromycin resistant M. genitalium infections in all three countries 
was consistent with de novo emergence of macrolide resistance mutations in about 
12% of initially wild-type infections. In the alternative scenarios, with the same 
estimated treatment rate, a lower probability of de novo resistance resulted in 
proportions of resistant M. genitalium infections below the lower confidence 
interval boundary of the observed data. 
The model estimated treatment rate and date of introduction of azithromycin were: 
France, treatment rate 0.07 y-1 (95% CI: 0.02 – 0.18 person-1 y-1), introduction of 
azithromycin in May 2000 (95% CI: October 1986 – June 2005); Denmark,  treatment 
rate of 0.13 y-1 (95% CI: 0.05 – 0.34 person-1 y-1), introduction of azithromycin in 
August 1996 (95% CI: November 1976 – January 2004); Sweden, treatment rate 0.14 
y-1 (95% CI: 0.11 – 0.17 person-1 y-1), introduction of azithromycin July 2006 (95% CI: 
January 2006 – November 2006). We also fitted the model to the data while 
assuming de novo resistance emergence probabilities of 1% or 0.1%, which resulted 
in higher estimated treatment rates and a lower goodness of fit (supplementary 
table 3). 
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Figure 3. Maximum likelihood fits (solid red lines) of the transmission model to the 
data of the relative prevalence of azithromycin resistant M. genitalium infections 
in France, Denmark and Sweden over time. The black data points correspond to 
reported proportions of resistant infections [3, 8, 10, 13, 31] (additional data from 
Denmark and Sweden provided by study authors). The error bars indicate the 95% 
confidence intervals. The red area is the 95% confidence interval of the model 
predictions. The dashed and dotted lines are simulations with probabilities of de 
novo emergence of resistance of 1% and 0.1% respectively, but with the treatment 
rate and time point of introduction obtained from the model fit. 
Figure 4 shows the relationship between the growth rate of the proportion of drug-
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resistant M. genitalium infections (∆𝜑) and the proportion of resistant infections for 
various treatment rates. The probability of de novo resistance emergence increases 
the growth rate of resistant infections across different initial values for the 
proportion of resistant infections. The relationship between ∆𝜑 and the proportion 
of resistant infections explains some of the dynamics of resistance spread. The 
growth advantage conferred by de novo emergence of resistant strains is always 
greatest at the time of introduction of antibiotic treatment, when the proportion of 
resistant strains is lowest.  
 
Figure 4. Relationship between the growth rate of the drug-resistant proportion of 
M. genitalium infections and the proportion of resistant infections for various 
treatment rates. The coloured solid lines show the growth rate for France (blue), 
Denmark (red), and Sweden (yellow) in the model with 12% probability of de novo 
emergence of drug resistance. The dashed and dotted lines are the growth rate in a 
model that uses the same treatment rate but probabilities of de novo emergence 
of resistance of 1% and 0.1% respectively. 
.CC-BY 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/321216doi: bioRxiv preprint first posted online May. 24, 2018; 
 15 
As the resistant strains spreads, the growth advantage diminishes, slowly 
approaching ∆𝜑 = 𝜒 according to Equation (6). Thus, the growth acceleration of 
resistant strains provided by de novo resistance reduces as the resistant strain 
spreads through the pathogen population. The curves for which we assumed a lower 
probability of de novo emergence or resistance are substantially flatter than the 
curve that results from the probability of de novo resistance estimated from the 
data. 
Discussion 
In this study, we obtained a summary estimate of the probability of de novo 
resistance of 12% (95% CI: 7 – 17%, 6 studies, I2 44%). In our model, applying this 
probability of de novo emergence of resistance during azithromycin therapy could 
explain observed increases in the proportion of azithromycin resistant M. genitalium 
infections in France, Denmark and Sweden. Lower probabilities of de novo resistance 
emergence, given the same estimated treatment rates, were not consistent with the 
observed data. Model-based estimates of the approximate time point of 
introduction of azithromycin were consistent with published descriptions.  
Strengths and weaknesses 
A strength of this study is the use of empirical data sources and mathematical 
modelling. We established a compartmental model to simulate the population 
dynamics of the spread of resistant M. genitalium and gathered the necessary 
parameter values from the literature. We obtained our estimate of the probability of 
de novo resistance from a systematic review and meta-analysis of six studies. 
.CC-BY 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/321216doi: bioRxiv preprint first posted online May. 24, 2018; 
 16 
Parameters that were not available in the literature were estimated by fitting the 
model to observational data from France, Denmark, and Sweden, including 
unpublished data. Comparing the data and model estimates for those countries also 
enabled us to compare the outcome of treatment strategies for NGU and M. 
genitalium infections. Despite its simplicity, the model assumptions provide a 
coherent qualitative explanation for the quantitative description of the clinically 
observed rapid rise of macrolide resistant M. genitalium infections. 
There are some caveats to both the observational data sources and the model. First, 
owing to the small number of samples for each data point, particularly for early 
years, confidence intervals for those estimates of the proportion of resistant 
infections are wide. In Denmark, azithromycin has been used for a long time but data 
about the prevalence of drug resistant infections were only available since 2006, 
which introduces more uncertainty in the estimated point at which resistance 
emerged. Second, the characteristics of people tested for M. genitalium in the three 
countries are not well described and differences in testing practices between 
countries might account for some of the variation in the proportions with macrolide 
resistance. An increase over time in the proportion of resistant infections was, 
however, observed in all three countries. We used a relatively simple transmission 
model, so we made several simplifying assumptions. First, we assumed that 
treatment rates in each country were constant over time and did not account for the 
possibility that azithromycin use might have risen over time. Second, we assumed 
that no second line treatments were used for resistant M. genitalium infections. If 
we implemented treatment of resistant infections, our estimates for the initial 
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treatment rate for susceptible infections would have been somewhat higher. In 
practice, since most M. genitalium infections are asymptomatic and diagnostic 
testing is still uncommon, we do not think that this simplification affected our 
conclusions. Third, our model does not include detailed population structure 
because the rate at which the relative proportion of resistant bacterial strains spread 
in a population can often be explained by the treatment rate, rather than the sexual 
network structure [26]. More complex models with different sexes, partner change 
rates, age structure, and a better understanding of the average infectious duration 
of M. genitalium, would be necessary to obtain a better description of the absolute 
prevalence of infections and resistance, but this was not the objective of this study. 
Interpretation and comparison with other studies  
This study strongly suggests that, rather than resulting in ‘occasional treatment 
failure’ as originally believed [18], the development of de novo resistant mutations in 
12% (95% CI: 7 – 17%) of M. genitalium infections is the main driver of azithromycin 
resistance. The data from France and Sweden [3, 8, 10, 31], where no macrolide 
resistant mutations were detected initially, show a substantial proportion of 
diagnosed M. genitalium infections with azithromycin resistance after just a few 
years of azithromycin use. Our model shows that a high de novo resistance 
acquisition rate contributes considerably to the spread of resistance, particularly 
during the early stages of its occurrence. The effect then decreases as the proportion 
of resistant infections increases. This pattern contrasts with a scenario in which 
resistance emerges with a lower probability. Then, the effect on the growth rate 
would be substantially smaller and the growth dynamics of the drug resistant 
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proportion are much closer to a logistic growth model. Assuming the same 
treatment rate, this growth dynamic would require much more time to reach the 
levels of resistance that we observed in France, Denmark and Sweden. We have not 
found any other mathematical modelling studies that have investigated the role of 
de novo mutations in the spread of antimicrobial resistant M. genitalium. Our model-
predicted estimates of the introduction of azithromycin for the treatment of NGU 
were consistent with published data describing its use in France [32] and Denmark in 
the 1990s, but later introduction in Sweden [10]. Our estimated treatment rate for 
France was lower than those for Denmark and Sweden but the 95% confidence 
intervals of all three estimates overlap. The estimated rates in Sweden and Denmark 
are very close to those estimated in another epidemiological model of M. genitalium 
infections in the United Kingdom [34]. 
The high probability of de novo emergence of macrolide resistance mutations during 
treatment of M. genitalium infections appears to differ from experiences with some 
other sexually transmitted bacterial infections. A 1g dose of azithromycin might 
often be insufficient to eradicate a M. genitalium infection in concert with host 
immune responses, allowing for either a resistance mutation to occur in the single 
23S rRNA operon during treatment or the survival of a few pre-existing drug-
resistant bacteria and the subsequent selection of the mutants. The latter 
explanation is favoured by the strong association with de novo resistance and high 
organism load [19, 21, 35], but both mechanisms may play a role. In the absence of 
any observable fitness cost, or of routine tests to detect macrolide resistance 
mutations, resistance to azithromycin has emerged and spread rapidly. In contrast, 
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selection pressure exerted by treatment and clonal spread are the major drivers of 
the spread of antimicrobial resistant Neisseria gonorrhoeae, with de novo resistance 
considered to be negligible [26]. N. gonorrhoeae has four copies of the 23S rRNA 
gene and resistance increases with the number of mutated copies [36]. In addition, 
active measures, such as combination therapy with ceftriaxone, are used to limit the 
potential for the emergence of de novo macrolide resistance in N. gonorrhoeae. 
Azithromycin resistance is also recognised in Treponema pallidum [37] but 
azithromycin monotherapy is not recommended as treatment for syphilis. 
Transmitted resistance is assumed to be responsible for most antimicrobial 
resistance, but a high rate of de novo resistance emergence has been observed 
during treatment with various antibiotics of other bacterial infections, such as 
Pseudomonas aeruginosa and Enterobacteriaceae [38–40]. In general, de novo 
selection of drug-resistant mutants within a single patient occurs more often if the 
resistance is mediated by single-base mutations than if acquisition of efflux pumps 
or other complex mechanism are needed [41]. Thus, it is distinct from the selection 
of drug resistance as a result of treatment at the population level which is more 
often transmitted; a situation which is seen with most other bacterial and parasitic 
sexually transmitted infections.  
Implications for research and practice 
The high level of azithromycin resistance in M. genitalium, driven by de novo 
resistance, poses problems for clinical management and population level control 
strategies [42]. There is an absence of evidence that screening for asymptomatic M. 
genitalium would be beneficial [42]. The focus should be on strategies to improve 
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surveillance of antimicrobial resistant M. genitalium infections and to improve the 
management of symptomatic infection, whilst minimising the emergence of 
resistance. Calls to abandon treatment of uncomplicated NGU with single dose 
azithromycin [23, 43–45] and to return to doxycycline [46] are increasing. Despite 
concerns about limited efficacy of doxycycline, a large randomised controlled trial 
conducted in the US from 2007 to 2011 found that both clinical and microbiological 
cure rates for doxycycline and azithromycin were comparable [47]. Evidence for the 
effectiveness of higher doses or extended regimens of azithromycin is mixed and the 
proportions of patients that develop macrolide resistance mutations with single dose 
and a five-day regimen were comparable in one study [21]. Resistance to second line 
treatment with the fluoroquinolone moxifloxacin is also increasing. New 
antimicrobials or combination therapy that might have a lower propensity for the 
emergence of de novo resistance are being investigated [48]. Implementation of 
clinical guidelines could help to improve consistent management. The first European 
guidelines for the management of M. genitalium and updated guidelines for NGU 
[46, 49], both published in 2016, recommend that a test to detect macrolide 
resistance mutations should accompany diagnostic testing for M. genitalium. Large 
trials are now needed to determine whether treatment regimens and algorithms, 
based on the results of resistance testing and follow-up tests of cure, can reduce the 
emergence of M. genitalium resistance. Since de novo mutations are the main driver 
of azithromycin resistance in M. genitalium, clinical management strategies should 
seek to limit the unnecessary use of macrolides. 
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